Arvinas Inc.
Clinical trials sponsored by Arvinas Inc., explained in plain language.
-
New pill takes aim at Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-stage trial tests an experimental pill, ARV-393, in 255 adults with advanced non-Hodgkin's lymphoma that has come back or not responded to prior treatments. The drug works by breaking down a protein that helps these cancer cells grow. The main goals are to check safety…
Phase: PHASE1 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated May 26, 2026 11:28 UTC
-
New drug targets Hard-to-Treat cancers by breaking down mutant protein
Disease control Recruiting nowThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the faulty protein that helps tumors grow. The study has two parts: first, finding safe doses in small groups, then testing the bes…
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC